These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 26700955)

  • 1. Novel Cytochrome P450 Reaction Phenotyping for Low-Clearance Compounds Using the Hepatocyte Relay Method.
    Yang X; Atkinson K; Di L
    Drug Metab Dispos; 2016 Mar; 44(3):460-5. PubMed ID: 26700955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies.
    Wang L; Zhang D; Raghavan N; Yao M; Ma L; Frost CE; Maxwell BD; Chen SY; He K; Goosen TC; Humphreys WG; Grossman SJ
    Drug Metab Dispos; 2010 Mar; 38(3):448-58. PubMed ID: 19940026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reaction Phenotyping of Low-Turnover Compounds in Long-Term Hepatocyte Cultures Through Persistent Selective Inhibition of Cytochromes P450.
    Smith S; Lyman M; Ma B; Tweedie D; Menzel K
    Drug Metab Dispos; 2021 Nov; 49(11):995-1002. PubMed ID: 34407991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro sulfoxidation of thioether compounds by human cytochrome P450 and flavin-containing monooxygenase isoforms with particular reference to the CYP2C subfamily.
    Usmani KA; Karoly ED; Hodgson E; Rose RL
    Drug Metab Dispos; 2004 Mar; 32(3):333-9. PubMed ID: 14977868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro inhibition and induction of human liver cytochrome p450 enzymes by milnacipran.
    Paris BL; Ogilvie BW; Scheinkoenig JA; Ndikum-Moffor F; Gibson R; Parkinson A
    Drug Metab Dispos; 2009 Oct; 37(10):2045-54. PubMed ID: 19608694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of drug-drug interaction for silymarin.
    Doehmer J; Tewes B; Klein KU; Gritzko K; Muschick H; Mengs U
    Toxicol In Vitro; 2008 Apr; 22(3):610-7. PubMed ID: 18249085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro characterization of the metabolic pathways and cytochrome P450 inhibition and induction potential of BMS-690514, an ErbB/vascular endothelial growth factor receptor inhibitor.
    Hong H; Su H; Ma L; Yao M; Iyer RA; Humphreys WG; Christopher LJ
    Drug Metab Dispos; 2011 Sep; 39(9):1658-67. PubMed ID: 21673131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of human cytochrome P450 enzymes by licochalcone A, a naturally occurring constituent of licorice.
    He W; Wu JJ; Ning J; Hou J; Xin H; He YQ; Ge GB; Xu W
    Toxicol In Vitro; 2015 Oct; 29(7):1569-76. PubMed ID: 26100226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro oxidative metabolism of cajaninstilbene Acid by human liver microsomes and hepatocytes: involvement of cytochrome p450 reaction phenotyping, inhibition, and induction studies.
    Hua X; Peng X; Tan S; Li C; Wang W; Luo M; Fu Y; Zu Y; Smyth H
    J Agric Food Chem; 2014 Oct; 62(43):10604-14. PubMed ID: 25272989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of In Vitro Cytochrome P450 Inhibition and In Vitro Fate of Structurally Diverse N-Oxide Metabolites: Case Studies with Clozapine, Levofloxacin, Roflumilast, Voriconazole and Zopiclone.
    Giri P; Naidu S; Patel N; Patel H; Srinivas NR
    Eur J Drug Metab Pharmacokinet; 2017 Aug; 42(4):677-688. PubMed ID: 27853934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LKY-047: First Selective Inhibitor of Cytochrome P450 2J2.
    Phuc NM; Wu Z; O Y; Lee JH; Oh S; Song GY; Liu KH
    Drug Metab Dispos; 2017 Jul; 45(7):765-769. PubMed ID: 28461575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of cytochrome P450-mediated drug-drug interaction potential of orteronel and exposure changes in patients with renal impairment using physiologically based pharmacokinetic modeling and simulation.
    Lu C; Suri A; Shyu WC; Prakash S
    Biopharm Drug Dispos; 2014 Dec; 35(9):543-52. PubMed ID: 25264242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting the Potential for Cannabinoids to Precipitate Pharmacokinetic Drug Interactions via Reversible Inhibition or Inactivation of Major Cytochromes P450.
    Bansal S; Maharao N; Paine MF; Unadkat JD
    Drug Metab Dispos; 2020 Oct; 48(10):1008-1017. PubMed ID: 32587099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of multiple cytochrome P450 activities in metabolically inactivated human liver microsomes and roles of P450 2C isoforms in reaction phenotyping studies.
    Murayama N; Yajima K; Hikawa M; Shimura K; Ishii Y; Takada M; Uno Y; Utoh M; Iwasaki K; Yamazaki H
    Biopharm Drug Dispos; 2018 Feb; 39(2):116-121. PubMed ID: 29136681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utility of intersystem extrapolation factors in early reaction phenotyping and the quantitative extrapolation of human liver microsomal intrinsic clearance using recombinant cytochromes P450.
    Chen Y; Liu L; Nguyen K; Fretland AJ
    Drug Metab Dispos; 2011 Mar; 39(3):373-82. PubMed ID: 21148079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytochrome P450 inhibition using recombinant proteins and mass spectrometry/multiple reaction monitoring technology in a cassette incubation.
    Weaver R; Graham KS; Beattie IG; Riley RJ
    Drug Metab Dispos; 2003 Jul; 31(7):955-66. PubMed ID: 12814974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kinetic analysis of the activation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone by heterologously expressed human P450 enzymes and the effect of P450-specific chemical inhibitors on this activation in human liver microsomes.
    Patten CJ; Smith TJ; Murphy SE; Wang MH; Lee J; Tynes RE; Koch P; Yang CS
    Arch Biochem Biophys; 1996 Sep; 333(1):127-38. PubMed ID: 8806763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An extensive cocktail approach for rapid risk assessment of in vitro CYP450 direct reversible inhibition by xenobiotic exposure.
    Spaggiari D; Daali Y; Rudaz S
    Toxicol Appl Pharmacol; 2016 Jul; 302():41-51. PubMed ID: 27105555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human reductive halothane metabolism in vitro is catalyzed by cytochrome P450 2A6 and 3A4.
    Spracklin DK; Thummel KE; Kharasch ED
    Drug Metab Dispos; 1996 Sep; 24(9):976-83. PubMed ID: 8886607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions.
    Ogilvie BW; Zhang D; Li W; Rodrigues AD; Gipson AE; Holsapple J; Toren P; Parkinson A
    Drug Metab Dispos; 2006 Jan; 34(1):191-7. PubMed ID: 16299161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.